Nippon Life Global Investors Americas Inc. Trims Position in IQVIA Holdings Inc. (NYSE:IQV)

Nippon Life Global Investors Americas Inc. reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 9.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 43,330 shares of the medical research company's stock after selling 4,460 shares during the quarter. Nippon Life Global Investors Americas Inc.'s holdings in IQVIA were worth $8,515,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Smith Group Asset Management LLC purchased a new position in IQVIA during the fourth quarter valued at $1,616,000. Nordea Investment Management AB grew its stake in shares of IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock valued at $277,908,000 after purchasing an additional 452,029 shares during the period. Hickory Asset Management Inc. purchased a new stake in shares of IQVIA in the 4th quarter worth $941,000. Fifth Third Bancorp increased its holdings in IQVIA by 13.0% in the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company's stock worth $2,590,000 after acquiring an additional 1,521 shares in the last quarter. Finally, Graphene Investments SAS raised its holdings in IQVIA by 22.0% during the fourth quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company's stock valued at $2,948,000 after acquiring an additional 2,700 shares during the period. 89.62% of the stock is owned by institutional investors.

Analysts Set New Price Targets

IQV has been the topic of several research analyst reports. HSBC cut shares of IQVIA from a "buy" rating to a "hold" rating and decreased their price target for the stock from $260.00 to $160.00 in a research note on Friday. Truist Financial cut their price objective on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a research report on Thursday, April 10th. Morgan Stanley increased their price target on IQVIA from $245.00 to $250.00 and gave the stock an "overweight" rating in a report on Tuesday, February 11th. Mizuho reduced their price objective on IQVIA from $242.00 to $210.00 and set an "outperform" rating on the stock in a report on Wednesday, April 9th. Finally, Robert W. Baird reduced their price target on IQVIA from $212.00 to $210.00 and set a "neutral" rating for the company in a research report on Tuesday, January 21st. Eight investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $237.62.

IQVIA Stock Performance

Shares of IQV traded down $0.30 during trading hours on Friday, hitting $150.38. The stock had a trading volume of 1,333,062 shares, compared to its average volume of 1,420,530. The firm has a 50-day moving average price of $171.60 and a 200 day moving average price of $194.05. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a fifty-two week low of $135.97 and a fifty-two week high of $252.88. The firm has a market capitalization of $26.51 billion, a price-to-earnings ratio of 20.05, a PEG ratio of 1.99 and a beta of 1.46.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.